Table 3.
Demographic and clinical data.
| Stable-LTX (n = 63) | ARAD (n = 22) | CLAD (n = 41) | BOS (n = 30) | RAS (n = 11) | IPF (n = 23) | CF (n = 21) | |
|---|---|---|---|---|---|---|---|
| Age mean ± SD | 50.6 ± 14.3 | 50.4 ± 14.3 | 51.0 ± 13.5 | 49.8 ± 13.2 | 55.9 ± 14.0 | 51.7 ± 11.1 | 31.0 ± 11.7 |
| Gender F/M ratio | 0.966 | 0.953 | 0.906 | 1.042 | 0.500 | 0.381 | 1.286 |
| Diagnosis prior to TX | |||||||
| COPD n (%) | 37 (58.7) | 9 (40.9) | 18 (43.9) | 14 (46.6) | 6 (54.5) | – | – |
| IPF n (%) | 8 (12.6) | 7 (31.8) | 8 (19.5) | 6 (20.0) | 2 (18.8) | 23 (100.0) | 21 (100.0) |
| IPAH n (%) | 4 (6.3) | 1 (4.5) | 4 (9.7) | 3 (10.0) | 1 (9.0) | – | – |
| CF n (%) | 8 (12.6) | 5 (22.7) | 4 (9.7) | 4 (13.3) | – | – | – |
| Others n (%) | 5 (7.9) | – | 5 (12.1) | 3 (10.0) | 2 (18.8) | – | – |
| Type of TX | |||||||
| DLUTX n (%) | 52 (82.5) | 20 (90) | 33 (80.4) | 24 (80.0) | 9 (81.8) | – | – |
| SLUTX n (%) | 10 (15) | 2 (9.0) | 7 (17.0) | 5 (16.6) | 2 (18.1) | – | – |
| HLTX n (%) | 1 (1.5) | 0 (0.0) | 1 (2.4) | 1 (3.3) | – | – | – |
| CMV risk | |||||||
| D+/R− n (%) | 15 (23.8) | 5 (22.7) | 9 (21.1) | 8 (26.6) | 1 (9.0) | – | – |
| D+/R+ n (%) | 30 (47.6) | 10 (45.5) | 19 (46.3) | 15 (50.0) | 4 (36.3) | – | – |
| D−/R+ n (%) | 12 (19.0) | 4 (18.1) | 7 (17.0) | 4 (13.3) | 3 (27.2) | – | – |
| D−/R− n (%) | 5 (1.5) | 3 (15.0) | 6 (14.6) | 3 (10.0) | 3 (27.2) | – | – |
Stable LTX Lung transplantation, ARAD sa, CLAD chronic lung allograft dysfunction, BOS bronchiolitis obliterans syndrome, RAS restrictive allograft syndrome, IPF idiopathic pulmonary fibrosis, CF cystic fibrosis, n number of individuals, SD standard deviation;